ESMO: Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade) Physician's Weekly, 24 Sep 2020 Several clinical trials have showed that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1 inhibitor increases the overall…